title: Treatment with methotrexate and low-dose corticosteroids in sarcoidosis patients with cardiac lesions.
abstract: OBJECTIVE
  Our objective was to evaluate the effectiveness of combination therapy consisting of low-dose corticosteroids with weekly methotrexate in patients with cardiac sarcoidosis in whom long-term therapy is required. Combination therapy was selected because long-term standard corticosteroid therapy tends to result in various adverse effects and the steroid-sparing effects of methotrexate have been reported.
  
  
  METHODS
  This study was a small open-label study comparing long-term functional changes between patients who received combination therapy (5-15 mg/day of prednisolone and 6 mg/week of methotrexate) and patients who received corticosteroids alone. The comparative analysis was based on the following therapeutic indexes: ejection fraction (EF), left ventricular end-diastolic diameter (LVDd) on echocardiography, serum N-terminal fragment pro-brain natriuretic peptide (NT-proBNP) and cardiothoracic ratio (CTR) on plain chest radiographs.
  
  
  METHODS
  Seventeen patients with cardiac sarcoidosis were examined in the sarcoidosis clinic. Cardiac sarcoidosis was diagnosed based on the Japanese diagnostic guidelines published in 2006.
  
  
  RESULTS
  The EF was significantly stabilized in the combination therapy group but not in the corticosteroids alone group at three years after the first treatment. The CTR and NT-proBNP levels were significantly stabilized in the combination therapy group compared with those observed in the corticosteroids alone group at both three and five years after the first treatment. The LVDd values tended to be stable in the combination therapy group compared with those observed in the corticosteroids alone group. The combination therapy was associated with few adverse effects.
  
  
  CONCLUSIONS
  Weekly methotrexate therapy with daily small doses of corticosteroids stabilized the EF, CTR and NT-proBNP levels in the serum without eliciting adverse effects longitudinally.
authors.affiliation: Central Clinic, Clinical Research Center, Japan.
authors.forename: Sonoko
authors.initials: S
authors.lastname: Nagai
authors.forename: Takafumi
authors.initials: T
authors.lastname: Yokomatsu
authors.forename: Kiminobu
authors.initials: K
authors.lastname: Tanizawa
authors.forename: Kohei
authors.initials: K
authors.lastname: Ikezoe
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Handa
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Ito
authors.forename: Shunpei
authors.initials: S
authors.lastname: Ogino
authors.forename: Takateru
authors.initials: T
authors.lastname: Izumi
mesh_terms: D000368:Aged; D009202:Cardiomyopathies / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D004452:Echocardiography; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage*; D011239:Prednisolone / Q000008:administration & dosage*; D013902:Radiography, Thoracic; D012507:Sarcoidosis / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D013318:Stroke Volume; D016896:Treatment Outcome; D016277:Ventricular Function, Left / Q000502:physiology
chemical_list: D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D011239:Prednisolone; D008727:Methotrexate